Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

57.87USD
23 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$57.87
Open
--
Day's High
--
Day's Low
--
Volume
55
Avg. Vol
7,439,031
52-wk High
$60.45
52-wk Low
$46.01

BMY

Chart for BMY

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $94,902.55
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.70

Financials

  BMY Industry Sector
P/E (TTM): 21.09 31.70 32.66
EPS (TTM): 2.74 -- --
ROI: 18.60 15.41 14.88
ROE: 30.97 16.43 16.12

Wall Street ends up but off highs after Trump announcement, Fed minutes

NEW YORK U.S. stocks ended slightly firmer on Wednesday but off the day's highs as worries mounted over President Donald Trump's agenda and minutes from the latest Federal Reserve meeting suggested policymakers are worried about weak inflation. | Video

Aug 16 2017

US STOCKS-U.S. stocks set to open higher ahead of Fed minutes

* Futures up: Dow 50 pts, S&P 5.25 pts, Nasdaq 14.75 pts (Adds details, comments, updates price)

Aug 16 2017

US STOCKS-Futures higher ahead of Fed minutes

Aug 16 U.S. stock index futures were higher on Wednesday ahead of the minutes on the Federal Reserve's July policy meeting, which will offer clues on the future path of interest rate hikes.

Aug 16 2017

Bristol-Myers kidney cancer drug fails late-stage trial

Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

Aug 15 2017

UPDATE 1-Bristol-Myers kidney cancer drug fails late-stage trial

Aug 15 Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

Aug 15 2017

Bristol-Myers kidney cancer drug fails late-stage trial

Aug 15 Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

Aug 15 2017

BRIEF-Bristol-Myers Squibb announces topline results

* Bristol-Myers Squibb announces topline results from checkmate -214, a phase 3 study of opdivo in combination with yervoy in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma

Aug 15 2017

BRIEF-Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics

* Regen Biopharma Inc addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics Source text for Eikon: Further company coverage:

Aug 10 2017

Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline

Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.

Aug 03 2017

Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline

Aug 3 Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.

Aug 03 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.80 --
Pfizer Inc. (PFE.N) $33.24 --
Merck & Co., Inc. (MRK.N) $62.15 --
Sanofi SA (SASY.PA) €82.15 +0.35
AstraZeneca plc (AZN.L) 4,519.00 +24.00
GlaxoSmithKline plc (GSK.L) 1,525.00 +8.00
Eli Lilly and Co (LLY.N) $78.15 --
Roche Holding Ltd. (ROG.S) CHF243.10 +0.20
Roche Holding Ltd. (RO.S) CHF246.70 -0.20

Earnings vs. Estimates